Biomarin announces first quarter 2012 financial results
BioMarin Pharmaceutical Inc. announced financial results for the first quarter of 2012. GAAP net loss was $24.0 million ($0.21 per diluted share) for the first quarter of 2012, compared to GAAP net loss of $4.4 million ($0.04 per diluted share) for the first quarter of 2011. Non–GAAP adjusted EBITDA was a loss of $0.1 million for the first quarter of 2012, compared to non–GAAP adjusted EBITDA of $17.3 million for the first quarter of 2011. Non–GAAP adjusted EBITDA excludes depreciation and amortization, contingent consideration expense, interest income and expense, income taxes, stock compensation expense and material non–recurring items.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.